Shares of CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $20.19.
CYRX has been the subject of several analyst reports. Weiss Ratings raised CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Piper Sandler raised CryoPort to a “buy” rating in a report on Tuesday, October 13th. Guggenheim lifted their price target on CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Robert W. Baird set a $26.00 price target on CryoPort in a report on Tuesday, October 13th. Finally, Needham & Company LLC upped their price objective on CryoPort from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, August 7th.
Check Out Our Latest Analysis on CYRX
CryoPort Price Performance
NASDAQ:CYRX opened at $16.05 on Tuesday. The company’s fifty day moving average price is $16.93 and its 200-day moving average price is $13.42. CryoPort has a 1-year low of $7.61 and a 1-year high of $18.88. The firm has a market capitalization of $812.93 million, a P/E ratio of -17.83 and a beta of 1.89.
CryoPort (NASDAQ:CYRX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The business had revenue of $50.22 million for the quarter, compared to analyst estimates of $48.66 million. Equities analysts anticipate that CryoPort will post -0.83 EPS for the current fiscal year.
Insider Transactions at CryoPort
In related news, CEO Jerrell Shelton sold 28,800 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the sale, the chief executive officer owned 1,201,814 shares in the company, valued at approximately $17,919,046.74. This trade represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.50% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of CYRX. State of Wyoming acquired a new position in CryoPort in the 3rd quarter worth about $81,000. Counterpoint Mutual Funds LLC purchased a new position in CryoPort during the third quarter worth approximately $324,000. State of Alaska Department of Revenue acquired a new stake in CryoPort in the third quarter valued at approximately $40,000. Engineers Gate Manager LP acquired a new stake in CryoPort in the second quarter valued at approximately $518,000. Finally, Squarepoint Ops LLC grew its holdings in CryoPort by 685.1% in the second quarter. Squarepoint Ops LLC now owns 368,424 shares of the company’s stock valued at $5,784,000 after purchasing an additional 321,497 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.
CryoPort Company Profile
CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.
Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.
See Also
- Five stocks we like better than CryoPort
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.
